Antiatherogenic effects of n-3 fatty acids – evidence and mechanisms
Abstract
Overview
N-3 (omega-3) (polyunsaturated) fatty acids are thought to display a variety of beneficial
effects for human health. Clues to the occurrence of cardiovascular protective effects
have been, however, the spur for the first biomedical interest in these compounds, and are the
best documented. Historically, the epidemiologic association between dietary consumption of
n-3 fatty acids and cardiovascular protection was first suggested by Bang and Dyerberg, who
identified the high consumption of fish, and therefore, of fish oil-derived n-3 fatty acids, as the
likely explanation for the strikingly low rate of coronary heart disease events reported in the Inuit
population. Since their initial reports, research has proceeded in parallel to provide further evidence
for their cardioprotection and to understand underlying mechanisms. Decreased atherogenesis
is currently thought to be a part of the cardiovascular protection by n-3 fatty acids. This
article summarizes the evidence for such a claim and the mechanisms putatively involved. (Heart
International 2006; 3-4: 141-54)
Keywords
Coronary heart disease, Fish, Fish oil, Omega-3 fatty acids, n-3 fatty acids, Cardioprotection, Nutrigenomics
Article Information
Correspondence
Raffaele De Caterina, MD, PhD, Chair and Postgraduate School of Cardiology, “G. d’Annunzio” University – Chieti, Ospedale San Camillo de Lellis, Via C. Forlanini, 50, 66100 Chieti – Italy, rdecater@unich.it
Acknowledgements
We gratefully acknowledge the kind and expert editorial
help of Dr. Brunella Orlandi.
Further Resources
Trending Topic
Despite improved treatment of atherosclerotic cardiovascular disease, coronary artery disease (CAD) remains the leading cause of death and disability worldwide.1 Treatment of traditional risk factors, mainly low-density lipoprotein (LDL) cholesterol, is the foundation of atherosclerotic risk reduction. However, a considerable residual risk for cardiovascular disease (CVD) still exists despite reducing LDL cholesterol.2 Beyond traditional risk factors, other […]
Despite improved treatment of atherosclerotic cardiovascular disease, coronary artery disease (CAD) remains the leading cause of death and disability worldwide.1 Treatment of traditional risk factors, mainly low-density lipoprotein (LDL) cholesterol, is the foundation of atherosclerotic risk reduction. However, a considerable ...
Peripheral artery disease (PAD) is a severe manifestation of systemic atherosclerotic disease that commonly refers to lower-extremity arterial involvement. The global burden of PAD is estimated to involve over 200 million patients, with prevalence increasing by 24% over the past decade.1 In ...
There are several beneficial effects of statins on the progression of atherosclerosis, and there have been significant advancements in pharmacotherapies for atherosclerotic cardiovascular disease (ASCVD). However, substantial residual cardiovascular (CV) risk remains, and there is an unmet need to reduce ...
Cardiovascular disease (CVD) represents the prevailing cause of death in the United States.1 Cancer, accidents and other prevalent causes of death, have a multitude of pathophysiologic and mechanistic underpinnings leading to mortality. Meanwhile, the majority of CVD is primarily attributable ...
...
...
...
...
...
...
...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
